{"transactions":[{"id":4640188,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-10-14T20:07:18.000Z","date":"2026-10-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units granted under the Issuer's Amended and Restated 2020 Stock Incentive Plan. The restricted stock units vest on October 8, 2029, subject to the Reporting Person continuing his employment with the Issuer, and will entitle the Reporting Person to one share of the Issuer's common stock for each restricted stock unit that vests."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings include shares previously acquired through exempt transactions pursuant to the Issuer's employee stock purchase plan."}],"balance_after":261047,"source":{"system":"sec-edgar","filing":"0001890784-26-000006","document":"wk-form4_1792008434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000189078426000006/wk-form4_1792008434.xml","form_type":"4"}},{"id":941144,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-12T16:01:39.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 8, 2026. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on January 8, 2027."}],"balance_after":30000,"derivative":{"exercise_price":18.83,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001890784-26-000003","document":"wk-form4_1768251691.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000189078426000003/wk-form4_1768251691.xml","form_type":"4"}},{"id":1014264,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-10-23T16:11:53.000Z","date":"2025-10-21","kind":"grant","planned":false,"acquired":true,"shares":26680,"price":18.74,"value":499983.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Holdings include shares previously acquired through exempt transactions pursuant to the Issuer's employee stock purchase plan."}],"balance_after":159751,"source":{"system":"sec-edgar","filing":"0001890784-25-000005","document":"wk-form4_1761250310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000189078425000005/wk-form4_1761250310.xml","form_type":"4"}},{"id":1035703,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-09-19T16:45:00.000Z","date":"2025-09-18","kind":"grant","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on September 18, 2025. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on September 18, 2026."}],"balance_after":50000,"derivative":{"exercise_price":19.23,"expiration_date":"2035-09-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001890784-25-000003","document":"wk-form4_1758314696.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000189078425000003/wk-form4_1758314696.xml","form_type":"4"}},{"id":1162615,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-01T18:17:22.000Z","date":"2025-04-29","kind":"grant","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest in four equal annual installments, with the first such installment occurring on January 12, 2026."}],"balance_after":75000,"derivative":{"exercise_price":17.85,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001599298-25-000097","document":"wk-form4_1746137834.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000159929825000097/wk-form4_1746137834.xml","form_type":"4"}},{"id":1162614,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-01T18:17:22.000Z","date":"2025-04-29","kind":"grant","planned":false,"acquired":true,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest in four equal annual installments, with the first such installment occurring on December 31, 2025."}],"balance_after":600000,"derivative":{"exercise_price":3.85,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001599298-25-000097","document":"wk-form4_1746137834.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000159929825000097/wk-form4_1746137834.xml","form_type":"4"}},{"id":1303640,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-14T16:06:34.000Z","date":"2025-01-12","kind":"grant","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not Applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 12, 2025. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on January 12, 2026."}],"balance_after":75000,"derivative":{"exercise_price":17.85,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001599298-25-000036","document":"wk-form4_1736888785.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000159929825000036/wk-form4_1736888785.xml","form_type":"4"}},{"id":1407834,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-09-13T17:26:07.000Z","date":"2024-09-11","kind":"grant","planned":false,"acquired":true,"shares":22026,"price":22.7,"value":499990.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of September 11, 2024, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person at a purchase price of $22.70 per share. The transaction closed on September 13, 2024."}],"balance_after":131426,"source":{"system":"sec-edgar","filing":"0001599298-24-000135","document":"wk-form4_1726262759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000159929824000135/wk-form4_1726262759.xml","form_type":"4"}},{"id":1547953,"issuer":{"id":3477,"kind":"organization","name":"Summit Therapeutics Inc.","symbol":"SMMT"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-04T17:47:15.000Z","date":"2024-04-02","kind":"grant","planned":false,"acquired":true,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 2, 2024. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on April 2, 2025.  Note this does not include an additional 600,000 options which were granted on April 2, 2024 and are subject to the satisfaction of performance conditions based on market capitalization and revenue targets."}],"balance_after":600000,"derivative":{"exercise_price":3.85,"expiration_date":"2034-04-02","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001599298-24-000058","document":"wk-form4_1712267219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000159929824000058/wk-form4_1712267219.xml","form_type":"4"}},{"id":1773407,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:07.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":36.71,"expiration_date":"2033-01-03","underlying":"Class A common stock","underlying_shares":33500},"source":{"system":"sec-edgar","filing":"0000899243-23-019532","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000089924323019532/doc4.xml","form_type":"4"}},{"id":1773406,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:07.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":28.78,"expiration_date":"2032-05-20","underlying":"Class A common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-23-019532","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000089924323019532/doc4.xml","form_type":"4"}},{"id":1773405,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:07.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23438,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":23438},"source":{"system":"sec-edgar","filing":"0000899243-23-019532","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000089924323019532/doc4.xml","form_type":"4"}},{"id":1773404,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-26T16:30:07.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"derivative":{"exercise_price":137.47,"expiration_date":"2031-07-12","underlying":"Class A common stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-23-019532","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000089924323019532/doc4.xml","form_type":"4"}},{"id":1773403,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-09-26T16:30:07.000Z","date":"2023-09-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24089,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 28, 2023, by and among the Issuer, Biogen Inc. (\"Biogen\") and River Acquisition, Inc., the Issuer became a wholly-owned subsidiary of Biogen upon consummation of the merger (the \"Effective Time\"). At the Effective Time, (a) each of the Issuer's outstanding shares of Class A common stock and Class B common stock (collectively, \"Common Stock\") was canceled and extinguished and automatically converted into the right to receive $172.50 in cash (the \"Merger Consideration\"), without interest, less any withholding taxes, (b) each of the Issuer's outstanding restricted stock units (\"RSUs\") was automatically canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration,  (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) without interest, subject to any applicable withholding taxes, and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's Common Stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option, subject to any applicable withholding taxes. As a result, stock options with a per share exercise price equal to or greater than the Merger Consideration were canceled without additional consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-019532","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000089924323019532/doc4.xml","form_type":"4"}},{"id":1786062,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-09-07T16:11:39.000Z","date":"2023-09-05","kind":"sale","planned":false,"acquired":false,"shares":406,"price":169.2,"value":68695.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":24089,"source":{"system":"sec-edgar","filing":"0001209191-23-048601","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123048601/doc4.xml","form_type":"4"}},{"id":1803957,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-08-17T16:31:39.000Z","date":"2023-08-16","kind":"sale","planned":false,"acquired":false,"shares":210,"price":168.4184,"value":35367.864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":24495,"source":{"system":"sec-edgar","filing":"0001209191-23-046276","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123046276/doc4.xml","form_type":"4"}},{"id":1803956,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-08-17T16:31:39.000Z","date":"2023-08-15","kind":"sale","planned":false,"acquired":false,"shares":193,"price":169.055,"value":32627.615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":24705,"source":{"system":"sec-edgar","filing":"0001209191-23-046276","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123046276/doc4.xml","form_type":"4"}},{"id":1852717,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-06-16T16:03:40.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":false,"shares":1562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date."}],"balance_after":23438,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":1562},"source":{"system":"sec-edgar","filing":"0001209191-23-037802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123037802/doc4.xml","form_type":"4"}},{"id":1852716,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-06-16T16:03:40.000Z","date":"2023-06-14","kind":"sale","planned":false,"acquired":false,"shares":2343,"price":102.1118,"value":239247.9474,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $101.9841 to $102.52 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":24898,"source":{"system":"sec-edgar","filing":"0001209191-23-037802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123037802/doc4.xml","form_type":"4"}},{"id":1852715,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-06-16T16:03:40.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":true,"shares":1562,"price":27.32,"value":42673.84,"ownership":{"direct":true},"balance_after":27241,"source":{"system":"sec-edgar","filing":"0001209191-23-037802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123037802/doc4.xml","form_type":"4"}},{"id":1889511,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-05-17T16:26:02.000Z","date":"2023-05-16","kind":"sale","planned":false,"acquired":false,"shares":136,"price":81.1038,"value":11030.1168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."}],"balance_after":25679,"source":{"system":"sec-edgar","filing":"0001209191-23-030181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123030181/doc4.xml","form_type":"4"}},{"id":1889510,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-05-17T16:26:02.000Z","date":"2023-05-15","kind":"sale","planned":false,"acquired":false,"shares":950,"price":85.9833,"value":81684.135,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $85.92 to $86.00 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":25815,"source":{"system":"sec-edgar","filing":"0001209191-23-030181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123030181/doc4.xml","form_type":"4"}},{"id":1963633,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-03-08T17:08:07.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":165,"price":84.58,"value":13955.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $84.56 to $84.59. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":26765,"source":{"system":"sec-edgar","filing":"0001209191-23-017248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123017248/doc4.xml","form_type":"4"}},{"id":1969494,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-03-06T16:31:27.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":820,"price":87.47,"value":71725.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this line represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $87.38 to $87.64. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":26930,"source":{"system":"sec-edgar","filing":"0001209191-23-016281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123016281/doc4.xml","form_type":"4"}},{"id":1980069,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right-to-buy)","published_at":"2023-03-02T17:15:07.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 20, 2022, the reporting person was granted an option to purchase 6,000 shares of Class A common stock. On March 1, 2023, based on the satisfaction of certain performance criteria, the options will vest on March 15, 2023, subject to continued service through the vesting date."}],"balance_after":6000,"derivative":{"exercise_price":28.78,"expiration_date":"2032-05-20","underlying":"Class A common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-23-014817","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123014817/doc4.xml","form_type":"4"}},{"id":1980068,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-03-02T17:15:07.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units granted with performance criteria (PSUs). On May 20, 2022, the reporting person was granted 3,000 PSUs. On March 1, 2023, based on the satisfaction of certain performance criteria, the PSUs will vest on March 15, 2023, subject to continued service through the vesting date."}],"balance_after":27750,"source":{"system":"sec-edgar","filing":"0001209191-23-014817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123014817/doc4.xml","form_type":"4"}},{"id":2068663,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right-to-buy)","published_at":"2023-01-04T16:07:22.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":33500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date."}],"balance_after":33500,"derivative":{"exercise_price":36.71,"expiration_date":"2033-01-03","underlying":"Class A common stock","underlying_shares":33500},"source":{"system":"sec-edgar","filing":"0001209191-23-000851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123000851/doc4.xml","form_type":"4"}},{"id":2068662,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2023-01-04T16:07:22.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":8250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units, which vest 1/16th of each grant on March 6, May 15, August 15, and November 15 of each year, subject to continued service through each vesting date."}],"balance_after":24750,"source":{"system":"sec-edgar","filing":"0001209191-23-000851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919123000851/doc4.xml","form_type":"4"}},{"id":2444556,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-05T16:10:18.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":27.32,"expiration_date":"2032-01-03","underlying":"Class A common stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-001640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919122001640/doc4.xml","form_type":"4"}},{"id":2444555,"issuer":{"id":12293,"kind":"organization","name":"REATA PHARMACEUTICALS INC","symbol":"RETA"},"owners":[{"id":69529,"kind":"person","name":"Anand Bhaskar","position":1,"cik":"0001890784","reported_name":"Anand Bhaskar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Chief Accounting Officer"}}],"security":"Class A common stock","published_at":"2022-01-05T16:10:18.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares represent Restricted Stock Units, which vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date."}],"balance_after":16500,"source":{"system":"sec-edgar","filing":"0001209191-22-001640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1890784/000120919122001640/doc4.xml","form_type":"4"}}]}